Image
Recommendation
Neoadjuvant chemotherapy – Regimens
Suitable neoadjuvant chemotherapy regimens include those used for adjuvant chemotherapy. Consider the addition of a platinum-based agent for patients with triple negative cancer.
For people with triple-negative invasive breast cancer, consider a neoadjuvant chemotherapy regimen that contains both a platinum and an anthracycline
Anthracycline-taxane-based chemotherapy combinations should be considered for all patients receiving neoadjuvant chemotherapy
Useful Links
How this guidance was developed
This recommendation was adapted from two source recommendations, one from SIGN (2013) and one from the NICE 2018 guidelines (UK). The NICE source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording ('Consider') indicative of a conditional recommendation (using GRADE methods) by the source guideline authors. The SIGN recommendation was not graded. The source recommendations were merged and simplified, including removal of the specification of ‘anthracycline-taxane regimens’ and inclusion, instead, of a link to eviQ.
Neoadjuvant chemotherapy – Regimens
Recommendation
Suitable neoadjuvant chemotherapy regimens include those used for adjuvant chemotherapy. Consider the addition of a platinum-based agent for patients with triple negative cancer.
Principles in action
Safe and quality care
Image
Communication
Useful Links
This recommendation was adapted from two source recommendations, one from SIGN (2013) and one from the NICE 2018 guidelines (UK). The NICE source recommendation was based on a systematic review of the evidence conducted to September 2017 and used wording ('Consider') indicative of a conditional recommendation (using GRADE methods) by the source guideline authors. The SIGN recommendation was not graded. The source recommendations were merged and simplified, including removal of the specification of ‘anthracycline-taxane regimens’ and inclusion, instead, of a link to eviQ.